Managing diabetes can be challenging, but the Diabeloop DBLG1 System offers a groundbreaking solution to simplify this process. Developed by Diabeloop, a French company specializing in therapeutic artificial intelligence, this Automated Insulin Delivery (AID) system combines cutting-edge technology with user-friendly features to help individuals with type 1 diabetes maintain optimal blood glucose levels. Let’s explore how the DBLG1 System works and why it’s making waves in diabetes management.
What Is the DBLG1 System?
The DBLG1 System is an advanced AID solution that integrates a Continuous Glucose Monitor (CGM), an insulin pump, and a dedicated handset running Diabeloop’s self-learning algorithm. Founded in 2015, Diabeloop has focused on leveraging artificial intelligence to improve the lives of people with diabetes, and the DBLG1 is a testament to their innovative approach.
System Specifications
Components:
- CGM: Monitors real-time glucose levels.
- Insulin Pump: Delivers precise amounts of insulin.
- Handset with Algorithm: Calculates and adjusts insulin delivery based on user data and real-time inputs.
Size and Weight:
Depends on the specific CGM and insulin pump models used.
Cartridge Size:
Varies with different insulin pumps but typically accommodates up to 300 units of insulin.
Basal Rates and Bolus Delivery:
Fully customizable to meet individual needs.
Water Resistance:
Varies by device; consult the user manuals of the pump and CGM for details.
How Does It Work?
The DBLG1 System uses a self-learning algorithm that continuously analyzes real-time data from the CGM and user-provided information, such as meals and activity levels. The system adjusts the insulin pump’s basal rates and delivers corrective boluses as needed to keep blood glucose levels within a target range. This adaptability reduces the risk of both high and low blood sugar events.
Algorithm Development
The DBLG1 algorithm was developed by Diabeloop in collaboration with research institutions and has undergone continuous refinement since its creation. It is designed to learn from each user’s unique patterns, improving the precision of insulin delivery over time.
Target Glucose Levels
The system aims to maintain glucose levels within 70 to 180 mg/dL (3.9 to 10 mmol/L). Users can personalize their target glucose settings in consultation with their healthcare provider.
Regulatory Approval
The DBLG1 System received CE marking in November 2018, authorizing its use in Europe. As of now, it is not available in the United States but is undergoing clinical studies to support future FDA approval.
Cost and Insurance
Pricing for the DBLG1 System varies by region and insurance coverage. To obtain specific cost details, users are encouraged to consult their healthcare provider or insurance company.
What’s Included?
When purchasing the DBLG1 System, users receive:
- A dedicated handset hosting the self-learning algorithm
- A compatible insulin pump (e.g., Kaleido or Dana-i)
- A compatible CGM (e.g., Dexcom G6) Comprehensive training ensures users understand how to operate the system effectively.
Compatibility
The DBLG1 System is compatible with:
- CGMs: Dexcom G6
- Insulin Pumps: Kaleido, Dana-i This flexibility allows users to choose devices that best suit their preferences and lifestyle.
Mobile Application and Remote Access
The DBLG1 System operates through a dedicated handset rather than a mobile app, allowing users to:
- Deliver bolus doses
- Monitor CGM data in real time
- Adjust insulin settings Data can also be uploaded to secure cloud platforms for remote monitoring by healthcare providers.
Battery Maintenance
Battery life and maintenance depend on the specific CGM and insulin pump models used. Users should refer to the respective device manuals for detailed instructions.
Pros and Cons
Pros:
- Self-learning algorithm that personalizes insulin delivery.
- Compatibility with leading CGMs and insulin pumps.
- CE-marked for use in Europe, with a growing user base.
Cons:
- Not yet available in the United States.
- Physical size and weight vary based on device combinations.
Conclusion
The Diabeloop DBLG1 System is a promising advancement in diabetes technology, offering personalized and automated insulin delivery through its innovative algorithm and seamless integration of devices. By reducing the daily burden of diabetes management, the DBLG1 empowers users to focus on living their lives while maintaining better glucose control. For more information, visit Diabeloop’s official website or consult your healthcare provider.